{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:42:05Z","timestamp":1763664125740,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00228-019-02789-9","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T20:02:30Z","timestamp":1574712150000},"page":"291-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Incidence of Adverse Drug Reactions in High-Risk Pregnancy: A Prospective Cohort Study in Obstetric Intensive Care"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-981X","authenticated-orcid":false,"given":"Tatiana Xavier","family":"da Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Danielle","family":"de Almeida Pimenta Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla Karilline","family":"do Vale Bezerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine Johansson","family":"Azeredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rand Randall","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Gouveia","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"2789_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.17535.1","volume":"8","author":"SJE Stock","year":"2019","unstructured":"Stock SJE, Norman JE (2019) Medicines in pregnancy. F!000research 8:1\u20138. https:\/\/doi.org\/10.12688\/f1000research.17535.1","journal-title":"F!000research"},{"key":"2789_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/pds.21843","volume":"20","author":"JR Daw","year":"2011","unstructured":"Daw JR, Hanley GE, Greyson DL, Morgan SG (2011) Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 20:895\u2013902. https:\/\/doi.org\/10.1002\/pds.21843","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2789_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajog.2011.02.029","volume":"205","author":"AA Mitchell","year":"2011","unstructured":"Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hern\u00e1ndez-D\u00edaz S (2011) Medication Use During Pregnancy, With Particular Focus On Prescription Drugs: 1976\u20132008. Am J Obstet Gynecol. 205:1\u201317. https:\/\/doi.org\/10.1016\/j.ajog.2011.02.029","journal-title":"Am J Obstet Gynecol."},{"key":"2789_CR4","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/S0140-6736(00)03209-8","volume":"356","author":"I Lacroix","year":"2000","unstructured":"Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL (2000) Prescription of drugs during pregnancy in France. The Lancet. 356:1735\u20131736. https:\/\/doi.org\/10.1016\/S0140-6736(00)03209-8","journal-title":"The Lancet."},{"key":"2789_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2013-004365","volume":"4","author":"A Lupattelli","year":"2014","unstructured":"Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, M\u00e5rdby AC, Moretti ME, Drozd M, Panchaud A, H\u00e4meen-Anttila K, Rieutord A, Gjergja Juraski R, Odalovic M, Kennedy D, Rudolf G, Juch H, Passier A, Bj\u00f6rnsd\u00f3ttir I, Nordeng H (2014) Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 4:1\u201311. https:\/\/doi.org\/10.1136\/bmjopen-2013-004365","journal-title":"BMJ Open."},{"key":"2789_CR6","doi-asserted-by":"publisher","unstructured":"Costantine MM (2014) Physiologic and pharmacokinetic changes in pregnancy. Frontiers in Pharmacol. ;1\u20135. https:\/\/doi.org\/10.3389\/fphar.2014.00065","DOI":"10.3389\/fphar.2014.00065"},{"key":"2789_CR7","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.accpm.2016.06.005","volume":"35","author":"L Zieleskiewicz","year":"2016","unstructured":"Zieleskiewicz L, Chantry A, Duclos G, Bourgoin A, Mignon A, Deneux-Tharaux C, Marc L (2016) Intensive care and pregnancy: Epidemiology and general principles of management of obstetrics ICU patients during pregnancy. Anaesth Crit Care Pain Med. 35:S51\u2013S57. https:\/\/doi.org\/10.1016\/j.accpm.2016.06.005","journal-title":"Anaesth Crit Care Pain Med."},{"key":"2789_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/ACO.0000000000000189","volume":"28","author":"V Patil","year":"2015","unstructured":"Patil V, Jigajinni S, Wijayatilake DS (2015) Maternal critical care: One small step for woman, one giant leap for womankind. Curr Opin Anaesthesiol. 28:290\u2013299. https:\/\/doi.org\/10.1097\/ACO.0000000000000189","journal-title":"Curr Opin Anaesthesiol."},{"key":"2789_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00134-009-1707-x","volume":"36","author":"JJ Zwart","year":"2010","unstructured":"Zwart JJ, Dupuis JRO, Richters A, Ory F, Van Roosmalen J (2010) Obstetric intensive care unit admission: a 2-year nationwide population-based cohort study. Intensive Care Med. 36:256\u2013263. https:\/\/doi.org\/10.1007\/s00134-009-1707-x","journal-title":"Intensive Care Med."},{"key":"2789_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1053\/j.ackd.2013.01.014","volume":"20","author":"AG Kattah","year":"2013","unstructured":"Kattah AG, Garovic VD (2013) The management of hypertension in pregnancy. Adv Chronic Kidney Dis. 20:229\u2013239. https:\/\/doi.org\/10.1053\/j.ackd.2013.01.014","journal-title":"Adv Chronic Kidney Dis."},{"key":"2789_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijoa.2018.08.011","volume":"37","author":"Z Edwards","year":"2019","unstructured":"Edwards Z, Lucas DN, Gauntlett R (2019) Is training in obstetric critical care adequate? An international comparison. International Journal of Obstetric Anesthesia. 37:96\u2013105. https:\/\/doi.org\/10.1016\/j.ijoa.2018.08.011","journal-title":"International Journal of Obstetric Anesthesia."},{"key":"2789_CR12","volume-title":"Recommendations for Prevention and treatment of pre-eclampsia and eclampsia","author":"WHO","year":"2011","unstructured":"WHO (2011) Recommendations for Prevention and treatment of pre-eclampsia and eclampsia. World Health Organization, Geneva"},{"key":"2789_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2393-13-34","volume":"5","author":"JM Smith","year":"2013","unstructured":"Smith JM, Lowe RF, Fullerton J, Currie SM, Harris L, Felker-kantor E (2013) An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC pregnancy childbirth. 5:13\u201334. https:\/\/doi.org\/10.1186\/1471-2393-13-34","journal-title":"BMC pregnancy childbirth."},{"key":"2789_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1055\/s-0033-1358770","volume":"31","author":"MS Wilson","year":"2014","unstructured":"Wilson MS, Ingersoll M, Meschter E, Bodea-Braescu AV, Edwards RK (2014) Evaluating the side effects of treatment for preterm labor in a center that uses high-dose magnesium sulfate. Am J Perinatol. 31:711\u2013716. https:\/\/doi.org\/10.1055\/s-0033-1358770","journal-title":"Am J Perinatol."},{"key":"2789_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000117797","volume":"17","author":"AE Omu","year":"2008","unstructured":"Omu AE, Al-Harmi J, Vedi HL, Mlechkova L, Sayed AF, Al-Ragum NS (2008) Magnesium sulfate therapy in women with pre-eclampsia and eclampsia in Kuwait. Med Princ Pract. 17:227\u2013232. https:\/\/doi.org\/10.1159\/000117797","journal-title":"Med Princ Pract."},{"key":"2789_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1471-2393-13-195","volume":"13","author":"ES Bain","year":"2013","unstructured":"Bain ES, Middleton PF, Crowther CA (2013) Maternal adverse effects of different antenatal magnesium sulfate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy Childbirth. 13:195","journal-title":"BMC Pregnancy Childbirth."},{"key":"2789_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jsps.2017.01.005","volume":"25","author":"AD Oliveira-Filho","year":"2017","unstructured":"Oliveira-Filho AD, Vieira AES, Silva RC, Neves SJF, Gama TAB, Lima RV, Oliveira WR, Dias JMG (2017) Adverse drug reactions in high-risk pregnant women: A prospective study. Saudi Pharm J. 25:1073\u20131077. https:\/\/doi.org\/10.1016\/j.jsps.2017.01.005","journal-title":"Saudi Pharm J."},{"key":"2789_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1037\/0012-1649.38.1.93","volume":"38","author":"R Levy-Shiff","year":"2002","unstructured":"Levy-Shiff R, Lerman M, Har-Even D, Hod M (2002) Maternal adjustment and infant outcome in medically defined high-risk pregnancy. Dev Psychol. 38:93\u2013103. https:\/\/doi.org\/10.1037\/0012-1649.38.1.93","journal-title":"Dev Psychol."},{"key":"2789_CR19","unstructured":"Schatz SN, Weber RJ (2015) Adverse drug reactions. Pharmacy Practice: 5\u201326"},{"key":"2789_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers MD, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245. https:\/\/doi.org\/10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"2789_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/00003246-198805000-00002","volume":"16","author":"S Lemeshow","year":"1988","unstructured":"Lemeshow S, Teres D, Avrunin JS, Gage RW (1988) Refining intensive care unit outcome prediction by using changing probabilities of mortality. Crit Care Med 16:470\u2013477 0090\u20133493\/88\/1965\u20130470$02.00\/0","journal-title":"Crit Care Med"},{"key":"2789_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2515\/therapie:2006058","volume":"61","author":"J Demotes-Maineard","year":"2006","unstructured":"Demotes-Maineard J, Canet E, Segard L (2006) Mod\u00e8les de partenariats Public-Priv\u00e9 en France et en Europe. Therapie. 61:313\u2013323. https:\/\/doi.org\/10.2515\/therapie:2006058","journal-title":"Therapie."},{"key":"2789_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/ejhpharm-2015-000751","volume":"23","author":"ET Johansen","year":"2016","unstructured":"Johansen ET, Haustreis SM, Mowinckel AS, Ytreb\u00f8 LM (2016) Effects of implementing a clinical pharmacist service in a mixed Norwegian ICU. Eur J Hosp Pharm. 23:197\u2013202. https:\/\/doi.org\/10.1136\/ejhpharm-2015-000751","journal-title":"Eur J Hosp Pharm."},{"key":"2789_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1053\/j.semperi.2013.04.001","volume":"37","author":"LA Hart","year":"2013","unstructured":"Hart LA, Sibai BM (2013) Seizures in pregnancy\u00a0: Epilepsy , eclampsia , and stroke. Seminars in Perinatology. 37:207\u2013224. https:\/\/doi.org\/10.1053\/j.semperi.2013.04.001","journal-title":"Seminars in Perinatology."},{"key":"2789_CR25","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.ajog.2003.12.057","volume":"190","author":"BM Sibai","year":"2004","unstructured":"Sibai BM (2004) Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol. 190:1520\u20131526. https:\/\/doi.org\/10.1016\/j.ajog.2003.12.057","journal-title":"Am J Obstet Gynecol."},{"key":"2789_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1471-0528.2006.01166.x","volume":"114","author":"Magpie Trial Follow-up Study Collaborative Group","year":"2007","unstructured":"Magpie Trial Follow-up Study Collaborative Group (2007) The Magpie trial: a randomised trial comparing magnesium sulfate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG 114:300\u2013309. https:\/\/doi.org\/10.1111\/j.1471-0528.2006.01166.x","journal-title":"BJOG"},{"key":"2789_CR27","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1034\/j.1600-0412.2001.801105.x","volume":"80","author":"R Begum","year":"2001","unstructured":"Begum R, Begum A, Johanson R, Ali MN, Akhter S (2001) A low dose (\u2018Dhaka\u2019) magnesium sulfate regime for eclampsia: Clinical findings and serum magnesium levels. Acta Obstet Gynecol Scand. 80:998\u20131002. https:\/\/doi.org\/10.1034\/j.1600-0412.2001.801105.x","journal-title":"Acta Obstet Gynecol Scand."},{"key":"2789_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2393-13-34","volume":"13","author":"JM Smith","year":"2013","unstructured":"Smith JM, Lowe RF, Fullerton J, Currie SM, Harris L, Felker-Kantor E (2013) An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth. 13:1\u201311. https:\/\/doi.org\/10.1186\/1471-2393-13-34","journal-title":"BMC Pregnancy Childbirth."},{"key":"2789_CR29","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0140-6736(15)00070-7","volume":"387","author":"BWJ Mol","year":"2016","unstructured":"Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ (2016) Pre-eclampsia. Lancet. 387:999\u20131011. https:\/\/doi.org\/10.1016\/S0140-6736(15)00070-7","journal-title":"Lancet."},{"key":"2789_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/1471-0528.13753","volume":"123","author":"BO Okusanya","year":"2016","unstructured":"Okusanya BO, Oladapo OT, Long Q, Lumbiganon P, Carroli G, Qureshi Z, Duley L, Souza JP, Gulmezoglu AM (2016) Clinical pharmacokinetic properties of magnesium sulfate in women with pre-eclampsia and eclampsia. BJOG. 123:356\u2013366. https:\/\/doi.org\/10.1111\/1471-0528.13753","journal-title":"BJOG."},{"key":"2789_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajog.2016.03.032","volume":"125","author":"R Beloosesky","year":"2016","unstructured":"Beloosesky R, Khatib N, Ginsberg Y, Anabosy S, Shalom-paz E, Dahis M, Ross MG, Weiner Z (2016) Maternal magnesium sulfate fetal neuroprotective effects to the fetus\u00a0: inhibition of neuronal nitric oxide synthase and nuclear factor kappa-light-chain-enhancer of activated B cells activation in a rodent model. Am J Obstet Gynecol 125:1\u20136. https:\/\/doi.org\/10.1016\/j.ajog.2016.03.032","journal-title":"Am J Obstet Gynecol"},{"key":"2789_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/jcph.941","volume":"57","author":"KF Brookfield","year":"2017","unstructured":"Brookfield KF, Elkomy M, Su F, Drover DR, Carvalho B (2017) Optimization of Maternal Magnesium Sulfate Administration for Fetal Neuroprotection: Application of a Prospectively Constructed Pharmacokinetic Model to the BEAM Cohort. J Clin Pharmacol. 57:1419\u20131424. https:\/\/doi.org\/10.1002\/jcph.941","journal-title":"J Clin Pharmacol."},{"key":"2789_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpeds.2016.06.053","volume":"178","author":"D Gano","year":"2016","unstructured":"Gano D, Ho MR, Patridge JC, Glass HC, Xu D, Barkovich AJ, Ferriero DM (2016) Antenatal exposure to magnesium sulfate is associated with reduced cerebellar hemorrhags in preterm newborns. J Pediatr. 178:68\u201374. https:\/\/doi.org\/10.1016\/j.jpeds.2016.06.053","journal-title":"J Pediatr"},{"key":"2789_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/14767058.2017.1279143","volume":"31","author":"G Vilchez","year":"2017","unstructured":"Vilchez G, Dai J, Lagos M, Sokol RJ (2017) Maternal side effects & fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. J Maternal-Fetal Neonatal Med 31:178\u2013183. https:\/\/doi.org\/10.1080\/14767058.2017.1279143","journal-title":"J Maternal-Fetal Neonatal Med"},{"key":"2789_CR35","doi-asserted-by":"publisher","unstructured":"Usman S, Foo L, Tay J, Bennett PR, Lees C (2017) Use of magnesium sulfate in preterm deliveries for neuroprotection of the neonate 19; 21\u201328. https:\/\/doi.org\/10.1111\/tog.12328","DOI":"10.1111\/tog.12328"},{"key":"2789_CR36","doi-asserted-by":"publisher","unstructured":"Chuan FS, Charles BG, Boyle RK, Rasiah L (2001) Population pharmacokinetics of magnesium in preeclampsia. Am J Obstet Gynecol.:593\u2013599. https:\/\/doi.org\/10.1067\/mob.2001.116726","DOI":"10.1067\/mob.2001.116726"},{"key":"2789_CR37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrneph.2014.103","volume":"10","author":"T Chaiworapongsa","year":"2014","unstructured":"Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, Yeo L, Romero R (2014) Pre-eclampsia part 2: prediction, preventions and management. Nat Rev Nephrol 10:531\u2013540. https:\/\/doi.org\/10.1038\/nrneph.2014.103","journal-title":"Nat Rev Nephrol"},{"key":"2789_CR38","doi-asserted-by":"crossref","unstructured":"Zuspan F (1966). Treatment of severe preeclampsia and eclampsia. Publishing in Clinical Obstetrics and gynecology. https:\/\/journals.lww.com\/clinicalobgyn\/Citation\/1966\/12000\/Treatment_of_Severe_Preeclampsia_and_Eclampsia.10.aspx. Acess in 22 jul 2019","DOI":"10.1097\/00003081-196612000-00010"},{"key":"2789_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.282.3.267","volume":"282","author":"LL Leape","year":"1999","unstructured":"Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erikson JI, Bates WB (1999) Pharmacist participation on physician ward rounds and adverse drug events in intensive care unit. J Am Med Assoc. 282:267\u2013270. https:\/\/doi.org\/10.1001\/jama.282.3.267","journal-title":"J Am Med Assoc."},{"key":"2789_CR40","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1590\/S0066-782X2009001300017","volume":"93","author":"CL Tedoldi","year":"2009","unstructured":"Tedoldi CL, Freire CMV (2009) Diretriz da Sociedade Brasileira de Cardiologia para Gravidez na Mulher Portadora de Cardiopatia. Arq Bras Cardiol. 93:e110\u2013e178. https:\/\/doi.org\/10.1590\/S0066-782X2009001300017","journal-title":"Arq Bras Cardiol."},{"key":"2789_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1447-0756.2007.00508.x","volume":"33","author":"BS Aali","year":"2007","unstructured":"Aali BS, Khazaeli P, Ghasemi F (2007) Ionized and total magnesium concentration in patients with severe preeclampsia-eclampsia undergoing magnesium sulfate therapy. J. Obstet. Gynaecol. Res. 33:138\u2013143. https:\/\/doi.org\/10.1111\/j.1447-0756.2007.00508.x","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"2789_CR42","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/0002-9378(87)90300-0","volume":"156","author":"JF Rodis","year":"1987","unstructured":"Rodis JF, Vintzileos AM, Campbell WA, Deaton JL, Nochimson DJ (1987) Maternal hypothermia: An unusual complication of magnesium sulfate therapy. Am J Obstet Gynecol. 156:435\u2013436. https:\/\/doi.org\/10.1016\/0002-9378(87)90300-0","journal-title":"Am J Obstet Gynecol."},{"key":"2789_CR43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1479-828X.2011.01303.x","volume":"51","author":"TM Crozier","year":"2011","unstructured":"Crozier TM, Wallace EM (2011) Obstetric admissions to an integrated general intensive care unit in a quaternary maternity facility. Austral New Zealand J Obstet Gynaecol 51:233\u2013238. https:\/\/doi.org\/10.1111\/j.1479-828X.2011.01303.x","journal-title":"Austral New Zealand J Obstet Gynaecol"},{"key":"2789_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00404-004-0721-z","volume":"274","author":"AS Al-Suleiman","year":"2006","unstructured":"Al-Suleiman AS, Qutub HO, Rahman J, Rahman MS (2006) Obstetric admissions to the intensive care unit: a 12-year review. Arch Gynecol Obstet. 274:4\u20138. https:\/\/doi.org\/10.1007\/s00404-004-0721-z","journal-title":"Arch Gynecol Obstet."},{"issue":"1","key":"2789_CR45","first-page":"137","volume":"32","author":"EPY Kam","year":"2004","unstructured":"Kam EPY, Eslick GD, McLean AS (2004) Obstetric critical care admissions: a 10-year retrospective review in an intensive care unit. Anaesthesia Intens Care. 32(1):137\u2013138","journal-title":"Anaesthesia Intens Care."}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02789-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02789-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02789-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T01:33:55Z","timestamp":1606181635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02789-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2789"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02789-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"5 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee Comit\u00ea de \u00c9tica em Pesquisa do Hospital Universit\u00e1rio Onofre Lopes and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}